TWEAK levels in psoriatic patients treated with narrowband ultraviolet B and methotrexate

Abstract

BackgroundPsoriasis is an autoimmune disease which has an effect on the joints and skin. Tumor Necrosis Factor‐Like Weak Inducer of Apoptosis (TWEAK) is a multi‐functional cytokine which regulates the cellular processes and has been related to a variation of conditions.ObjectivesTo measure the level of serum TWEAK in psoriatic diseased persons and its relationship to the PASI score pre‐ and post‐therapy with narrowband ultraviolet B phototherapy (NB‐UVB) and methotrexate (MTX).MethodsThis randomized controlled trial was conducted on 40 patients and 20 healthy persons as controls. Patient Group was randomly subdivided to two groups. The 1st group consisted of 20 patients who received NB‐UVB treatment. The 2nd group included 20 MTX‐treated candidates. Blood samples were drawn from patients in order to detect serum TWEAK levels using ELISA. The research was registered on Clinical Trials Registration: RCT approval numbers: NCT0481191.ResultsThe mean PASI score percent improvement after 12 weeks of treatment was higher in the MTX group (90%) than NB‐UVB group (60%). The serum TWEAK level at baseline was 60.47 ± 12.6 pg/mL in NB‐UVB group and 54.69 ± 21.7 pg/mL in MTX group which reduced to 24.93 ± 17.6 pg/mL and 32.13 ± 23.6 pg/mL, respectively (p < 0.001), after 12 weeks of treatment. There was a positive correlation between the serum levels of TWEAK and severity of PASI score (r = 0.399, p = 0.014).ConclusionTWEAK grades in psoriasis are substantially higher than in controls. TWEAK levels were dramatically reduced during NB‐UVB and MTX treatment. TWEAK may have a potential sign for psoriasis diagnosis and prognosis.